8.240USD-1.55%Mkt Cap: 445.43M USDP/E: —Last update: 2026-05-26
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of sev…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap445.43M USD
Enterprise Value166.93M USD
Revenue (TTM)3.32M USD
Gross Profit3.32M USD
Net Income (TTM)-143.44M USD
Revenue/Share0.0610 USD
Last Price8.240 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees75
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.80
PEG—
EV/EBITDA-0.97
EV/Revenue50.25
P/S138.59
P/B1.35
EPS (TTM)-2.90
EPS (Forward)-3.02
52W Range
7.2504% of range33.68
52W High33.68 USD
52W Low7.250 USD
Profitability
Gross Margin100.00%
Oper. Margin-4218.09%
EBITDA Margin0.00%
Profit Margin-5026.03%
ROE-42.22%
ROA-40.55%
Growth
Revenue Growth82.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-133.28M USD
CapEx (TTM)165.00K USD
FCF Margin-2718.57%
FCF Yield-20.28%
Net Debt-293.47M USD
Net Debt/EBITDA1.71
Balance Sheet
Debt/Equity0.00
Current Ratio23.14
Quick Ratio21.74
Book Value/Sh6.264 USD
Cash/Share5.413 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)42.43 USD
Target Range15.00 USD – 75.00 USD
# Analysts7
Ownership
Shares Out.54.42M
Float35.01M
Insiders14.88%
Institutions90.06%
Short Interest
Short Ratio5.3d
Short % Float9.13%
Short % Out.5.92%
Shares Short3.22M
Short (prev mo.)3.44M
Technical
SMA 509.292 (-11.3%)
SMA 20018.56 (-55.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)552.66K
Avg Vol (10d)659.10K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—